Being able to quantify, harness, and ultimately control the psychoactive effects of cannabis is key in making cannabis accessible to as many patients as possible, according to Perry Davidson, founder and CEO of Syqe. When Davidson was first founding Syqe, he noticed that a majority of patients were using cannabis to treat their chronic pain, and that inhalation was the most beneficial route of administration. Since that realization, Syqe has been working to perfect their inhalation system and make it controllable enough to be deliverable to a small child. Davidson notes that "a metered dose inhalation system would allow patients and physicians to be comfortable in that treatment paradigm of cannabis." In the end, the Syqe team decided to keep the flower in its full, raw form - no chemical alterations, no extractions.